NCT02500979 - Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 17, 2015

Primary Completion Date

August 5, 2016

Study Completion Date

August 5, 2016

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

Pramlintide acetate

Pramlintide acetate administered by a separate pump

DRUG

Placebo

Placebo administered by separate pump

DRUG

Lispro insulin U-100

Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)

DRUG

Regular insulin U-100

Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump

Trial Locations (3)

37411

Research Site, Chattanooga

91911

Research Site, Chula Vista

97239

Research Site, Portland